SHS

News

Symphony Health Solutions Appoints Frank Lavelle Chief Executive Officer
New Study on Physician Online Behaviors Shows Health Care Professional Sites Reach 4 out of 5 Physicians, While Electronic Medical Records Show Highest Engagement
"Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape" by Bill Bowman for the November issue of OBR
Symphony Health Solutions Launches ePrescribing Solutions Suite
Symphony Health Solutions Launches OnTrack ATU for Performance Tracking
Symphony Health Solutions Announces New Senior Executive Appointments
Symphony Health Solutions Adds Three Senior Executives and New Board Member
AlphaDetail, Healthcare Market Research Leader, Once Again Named to the Honomichl Top 50
Symphony Technology Group Acquires Source Healthcare Analytics from Wolters Kluwer; will Combine with Impactrx, TargetRx and Alphadetail to Create Symphony Health Solutions
ImpactRx Acquires AlphaDetail
AlphaDetail Inc. Names Anthony Quagliata to Position of Director, Sales & Marketing
AlphaDetail, Healthcare Market Research Specialist, Named to the Honomichl Top 50
AlphaDetail AlphaPulseTM: Anticipated Impact of CATT Trial in Wet AMD Treatment
AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering
AlphaDetail Revenue Soars 30% in 2010
Turning the Tables on Measuring Client Satisfaction
AlphaDetail Launches RapidRecruit: A New Healthcare Market Research Field and Tab Service
AlphaDetail Names Rishi Varma to Serve as President and CEO
Tracking Studies: The Advantage of Integration and Speed
Physicians Anticipate Higher Prescribing Based on JUPITER Study
AlphaDetail, Inc. Continues Bi-coastal Expansion
Most Practicing Physicians React Positively to FDA Panel’s Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
ASCO Results: Oncologists Rank Genentech Number One
AlphaDetail, Inc. Announces Launch of New Web-Based KOL Online Reporter (KOLORTM)
AlphaDetail, Inc. Expands Management Team
AlphaDetail, Inc. Expands Qualitative Research Capabilities
AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence

 

 

 

 

FOR IMMEDIATE RELEASE

New Study on Physician Online Behaviors Shows Health Care Professional Sites
Reach 4 out of 5 Physicians, While Electronic Medical Records Show Highest Engagement

More Than Half of Physicians Show Interest in Using Mobile Devices and Tablets at Work

Reston, VA, December 03, 2012

comScore, Inc. (NASDAQ: SCOR), a leader in measuring the digital world, today released new findings from a study based on data generated by the comScore/Symphony Health Care Professional (HCP) Measurement Solutions offering, which provides insight into the actual online behavior of physicians with regard to health-related categories, and the Physician Mobile Survey, a survey of physicians’ attitudes toward mobile devices and tablets in the workplace. Based on a longitudinal study of a permission-based panel of 1,000 U.S. physicians, the study showed that HCP Content websites such as Medscape.com, which provide content or services catering specifically to physicians, reached the highest percentage of physicians (81 percent) in comparison to other types of health sites. However, Electronic Medical Records sites such as Allscripts.com showed higher engagement as physicians have begun to use these sites to replace paper record-keeping. The study also revealed that although computers are still the most often used device to go online at work by physicians, more than half of physicians expressed interest in using mobile phones and tablets in the workplace.

“It has never been easier for physicians to access health information digitally in the workplace, which makes it important for health marketers to understand exactly how and when doctors are using online tools to do their work more efficiently,” said John Mangano, vice president for comScore Health and Pharmaceutical Solutions. “With the health industry placing more emphasis on the potential of mobile platforms, marketers must also educate themselves on how physicians are currently integrating – or plan to integrate – smartphones and tablets into their digital work habits.”

HCP Sites Reach Most Physicians, But Electronic Medical Records Show Highest Engagement
In Q1 2012, HCP Content sites reached the highest percentage of physicians at 81 percent and also showed the second-highest visitation frequency among different types of health sites. In contrast, Electronic Medical Records sites showed the lowest physician reach at only 4 percent, but exhibited the highest visitation frequency and most average time spent per physician for those now using electronic records to replace paper records. Physicians using tablets showed a greater propensity to access medical records on their tablets rather than mobile phones, suggesting that the reach of this category will likely only grow with further tablet adoption. Health Social Media sites (such as Sermo.com) now reach half of physicians going online, showing the largest growth in visitation over the past year. The Health Social Media category also had the largest share of visits from high-prescribing physicians, a priority target for many HCP marketers.

Percent Reach of Health Categories Among Physicians 
Q1 2012
Source: comScore/Symphony HCP Measurement Solutions

Health Category

% Reach of Physicians Online

Average Visits per Physician

Average Minutes per Physician

HCP Content

81%

14.6

5.1

General Health Content

72%

6.5

2.9

Association

61%

4.8

6.9

Government

51%

4.7

6.3

Health Social Media

50%

9.7

8.0

Pharma Support

47%

8.6

10.2

Pharmaceuticals

44%

3.3

3.6

Health & Wellness

39%

4.9

5.1

Insurance

34%

7.0

8.9

Physician Locator

33%

2.7

2.3

Medical Journal

30%

3.5

4.8

Clinic

25%

7.4

9.4

Pharmacy Services

18%

8.0

10.1

Electronic Medical Records

4%

18.4

18.0

Pharmaceutical Online Ad Exposure Exhibits Strong Correlation with Prescription Activity
Another aspect of the study examined the correlation between prescribing activity and exposure to pharmaceutical advertising. An analysis of high-prescribing physicians’ online behavior from Q1 2011 through Q1 2012 showed a strong correlation (R²=0.6557) between share of visits to Medscape properties among high-prescribing physicians and the number of pharmaceutical ad impressions to which they were exposed. While correlation does not necessarily imply causation, this strong positive association indicates the possibility of online ad exposure driving prescription activity.

Preference for Using Tablets Among Physicians Outpaces Actual Usage
A survey of more than 300 U.S. physicians owning mobile devices conducted in June 2012 showed, not surprisingly, that computers remained the most heavily-used electronic device in the workplace. More than three-quarters of physicians said they used their PCs on a daily basis to go online to access health content. As new platforms emerge, the results also showed that a significant 60 percent also reported using mobile phones on a daily basis, with 62 percent of these daily mobile users indicating they need their device to stay in contact with their job.

In addition, 44 percent reported using tablets every day. However, while mobile phones outpaced tablets in terms of actual use, a greater percentage of physicians reported a preference for using tablets in the workplace (64 percent vs. 55 percent). This disparity suggests the potential for further adoption of tablet usage among physicians in order to meet their stated preference. On tablets, the most heavily accessed pieces of content were medical news, drug information, and disease treatment options. Tablets also showed an advantage over mobile phones as a point of access for electronic medical records and health records.

Usage and Preference for Mobile Devices and Tablets
June 2012
Source: comScore Physicians Mobile Survey (n=315)

 

Mobile Phones

Tablets

% of Physicians Using Specified Device Everyday

60%

44%

% of Physicians Who Would Prefer to Use Specified Device

55%

64%

Interestingly, specialists showed a slightly higher propensity to use smartphones and tablets in the workplace, compared to primary care physicians. Moreover, there was no statistically significant difference in device usage between Baby Boomers and Generation X, meaning that physician age is less of a barrier to technology adoption than it is in the general population.

“While mobile phones have already emerged as a means for doctors to look up medical information quickly and efficiently, tablet usage is ramping up quickly and shows significant promise to serve as a substitute for computers in handling more involved tasks like record-keeping,” added Mangano.

To learn more about the comScore/Symphony HCP Measurement Solutions and the Physician Mobile Survey, please contact John Mangano at jmangano@comscore.com.

 

About comScore Health and Pharmaceutical Solutions

comScore Health and Pharmaceutical Solutions delivers in-depth information needed to understand the impact that brand, condition-specific, and health websites have on consumers’ brand awareness, conversion, and patient compliance, in addition to insights into health care professionals’ online usage. comScore products deliver actionable insights to help refine consumer profiles, evaluate and test creative campaign elements across traditional and digital media, identify key alliances, optimize interactive marketing initiatives, benchmark against the competition and accurately measure the ROI of web site and online marketing programs. For more information, please visit http://www.comscore.com/Industry_Solutions/Pharmaceutical.

About comScore/Symphony HCP Measurement Solutions and the Physicians Mobile Survey
In partnership with Symphony Health Solutions, comScore continually measures the online behavior of physicians via a 1,000-person permission-based HIPAA-compliant physician panel to determine behavioral trends linked to prescription activity and size market opportunities. The Physicians Mobile Survey cited in this release was fielded June 1, 2012 – June 12, 2012 with a sample size of 315 physicians.  The results shed light on how often and for what purposes physicians use mobile devices such as smartphones and tablets at work, in conjunction with desktop computers. The study also highlights differences in the types of medical content most likely to be accessed on each platform, as well as differences in how physicians of different specialties and demographic characteristics engage with mobile at work.

About comScore
comScore, Inc. (NASDAQ: SCOR) is a global leader in measuring the digital world and preferred source of digital business analytics. For more information, please visit www.comscore.com/companyinfo.

About Symphony Health Solutions
Symphony Health Solutions enables the growth of our clients and transformation of the healthcare ecosystem by providing best-in-class information, analytics and technology solutions with actionable insights for maximum impact. Comprised of AlphaDetail, ImpactRx, and Source Healthcare Analytics, the company connects and integrates a broad set of primary and secondary health research, analytics and consulting expertise to deliver high-value knowledge products that help our clients leverage the rich data available to transform their businesses.   For more information, visit: www.symphonyhealth.com.

For media information, please contact:

Heather Varela, Symphony Health Solutions
heather.varela@symphonyhealth.com
602.463.7838

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

Symphony Health Solutions Launches ePrescribing Solutions Suite

New Suite of Tools Measures Impact of Electronic Prescribing on Brand Performance

Phoenix, AZ, October 24, 2012

Source Healthcare Analytics, a Symphony Health Solutions Company, today launched ePrescribing Solutions Suite, a set of tools designed to benchmark how electronic prescribing influences brand performance compared to traditional forms of script submissions, such as paper, phone and fax.

Electronic prescribing has doubled over the last two years to 42 percent of new prescriptions written in the first half of 2012, according to Source data. Driven heavily by government incentives to physicians, e-prescriptions are also gaining popularity due to their fast, error-free delivery to the pharmacist. In response, ePrescribing Solutions Suite was developed as a means to help pharmaceutical brand teams understand how e-prescribing influences factors that determine brand performance. The product looks at the effect of e-prescribing on payer access, patient behavior and adherence, and helps fine-tune marketing efforts to account for this influence.

Powered by ProMetis®, the industry’s only fully integrated practitioner, payer, and patient claims data set, ePrescribing Solutions Suite is offered in three convenient modules, each geared to answer a specific business need. Using this suite, marketers can measure a physician’s propensity to e-prescribe, determine influence on payer impact, and whether patients are more likely to abandon, start or stay on a medication.

“As e-prescribing becomes fully adopted, it is increasingly problematic for brand managers as they attempt to triangulate on the specific issues driving patient and practitioner behavior. It is essential to understand the extent to which this practice is influencing the drivers of patient care,” said Karin Hayes, Senior Director, Product Management, Source Healthcare Analytics. “Our ePrescribing Solutions Suite offers brand teams the ability to confidently answer the important question:  Is e-prescribing hurting or helping my brand?”

Available immediately, more information about ePrescribing Solutions Suite can be accessed by visiting www.sourceha.com or by contacting a Source account representative.

About Symphony Health Solutions
Symphony Health Solutions enables the growth of our clients and transformation of the healthcare ecosystem by providing best-in-class information, analytics and technology solutions with actionable insights for maximum impact. Comprised of AlphaDetail, ImpactRx, and Source Healthcare Analytics, the company connects and integrates a broad set of primary and secondary health research, analytics and consulting expertise to deliver high-value knowledge products that help our clients leverage the rich data available to transform their businesses.   For more information, visit: www.symphonyhealth.com.

For media information, please contact:

Tom Kivett, Kivett & Company Communications
tkivett@kivettandco.com
212.727.2935

Heather Varela, Symphony Health Solutions
heather.varela@symphonyhealth.com
602.463.7838

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

Symphony Health Solutions Launches OnTrack ATU for Performance Tracking

Revolutionary Product Delivers Integrated Insights to Drive Biopharmaceutical Brand Performance

San Mateo, CA, October 17, 2012

AlphaDetail, a Symphony Health Solutions Company, today announced the launch of OnTrack ATU, a single-source biopharmaceutical brand performance tracking solution which integrates promotion, brand perceptions, prescribing, and dispensed Rx information.

OnTrack ATU provides a much-needed solution, enabling biopharmaceutical brand teams to effectively harmonize the disconnected information captured throughout the pharmaceutical promotion and treatment continuum.  It integrates data from several sources to provide a detailed analysis of how brand strategy and promotional efforts impact sales representative promotion, physician brand perceptions, written physician prescriptions and actual dispensed Rxs.

 “With OnTrack ATU, brand managers will no longer have to struggle with disjointed data that does not and cannot provide a complete brand picture,” explained Rishi Varma, President & CEO of AlphaDetail.  “OnTrack ATU brings together the power of our data – a unique blend of AlphaDetail’s custom ATU research, ImpactRx and Source data – with the strength of our experienced team to offer unique insight and information to brand managers. The insight and information offered by this revolutionary product is unrivaled in the market.” 

Available immediately, more information about OnTrack ATU can be accessed by visiting www.alphadetail.com or by contacting an AlphaDetail account representative.

About AlphaDetail
AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.alphadetail.com.

About Symphony Health Solutions
Symphony Health Solutions enables the growth of our clients and transformation of the healthcare ecosystem by providing best-in-class information, analytics and technology solutions with actionable insights for maximum impact. Comprised of AlphaDetail, ImpactRx, and Source Healthcare Analytics, the company connects and integrates a broad set of primary and secondary health research, analytics and consulting expertise to deliver high-value knowledge products that help our clients leverage the rich data available to transform their businesses.   For more information, visit: www.symphonyhealth.com.

For media information, please contact:

Tom Kivett, Kivett & Company Communications
tkivett@kivettandco.com
212.727.2935

Heather Varela, Symphony Health Solutions
heather.varela@symphonyhealth.com
602.463.7838

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

Symphony Health Solutions Announces New Senior Executive Appointments

Don Otterbein on board as SVP, Marketing & Product Management; Jeff Cottle named Chief People Officer

Horsham, PA, October 03, 2012

Symphony Health Solutions, owned by Palo Alto-based strategic equity firm Symphony Technology Group, today announced two more hires to its executive team including a new leader of Marketing and Product Management and a new head of Human Resources.  Don Otterbein was named Senior Vice President, Marketing & Product Management and Jeff Cottle was named Senior Vice President & Chief People Officer (CPO).  Both are based in Horsham, Pa., and are now active members of the Symphony Health Solutions executive team.

Prior to Joining Symphony Health, Don Otterbein held the position of VP, Life Sciences at Cognizant Technology Solutions, where he led their Sales & Marketing Practice in the development of new, innovative solutions.  Prior to this, Don had a long, diverse career at IMS Health, where from 1994 to 2010 he held a variety of global and regional leadership positions in business line management, offerings development, general management, consulting & services, and operations.  In his last role at IMS, he served as General Manager of the Business Transformation Services unit, leading a global consulting unit that provided commercial analytics, IT and business process outsourcing services to the commercial operations, market research and managed markets functions of leading pharmaceutical companies.  He holds a B.S. degree from Villanova University.
                                  
Jeff Cottle joins Symphony Health as SVP, Chief People Officer (CPO) in charge of Human Resources including organizational strategy, training and development, and talent management.  Cottle has a strong multi-decade history at SunGard as an HR executive, and was most recently Vice President, Human Resources Operations at SunGard’s Financial Systems Division, a technology solutions provider to the financial services markets.  Prior to this he served as SVP, Human Resources for SunGard Higher Education (now Ellucian) from 2002 – 2012.  In this role, he helped lead the integration of the acquired businesses of Collegis, Systems & Computer Technology Corporation (SCT) and BSR, Inc., into a highly profitable, growing combined business unit with 2,500+ employees, and was responsible for organizational development, global staffing and recruiting, as well as training, development and talent management programs.  Prior to SunGard, he held various HR-related positions at Drexel and Temple Universities.  He holds a B.A. degree from Temple University.
                                   
“Don and Jeff are both seasoned professionals with excellent relevance for our journey and our opportunities ahead with Symphony Health Solutions,” said Romesh Wadhwani, CEO, Symphony Technology Group.  “We are bringing together complementary insight capabilities and organizations with a goal of establishing a customer centric leader for our industry propelled by strong innovation.  Don brings deep industry knowledge of the pharmaceutical and health informatics industry and a highly successful track record running product development and business operations functions for technology and information services companies.  Jeff comes to us as a seasoned HR executive and change agent well suited to help us bring these capabilities together, as well as drive a strong organizational strategy and talent development.”

About AlphaDetail
AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.alphadetail.com.

About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry.  Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace.  Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions.  The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients.  These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning.  ImpactRx is a Symphony Health Solutions company (www.symphonyhs.com) and AlphaDetail (www.alphadetail.com) is ImpactRx’s global custom market research unit.  For more information, visit: www.impactrx.com.

About Symphony Health Solutions
Symphony Health Solutions provides comprehensive and multi-dimensional understanding of relevant information necessary to measure performance and inform strategies for optimal business decision-making. Focused on conveying value through information to the life sciences and healthcare industries, each of its units brings deep sector expertise and innovation in the delivery of insight to its client partners.

Comprised of AlphaDetail, ImpactRx, Source Healthcare Analytics and TargetRx, the company connects a broad set of research, analytics and health information products that together form a leading performance measurement group. On this strong collaborative platform, Symphony Health Solutions builds innovative solutions to unite information with insight, and deliver high-value knowledge products that enable clients to operate within an evolving healthcare ecosystem.  For more information, visit: www.symphonyhealth.com.

For media information, please contact:

Tom Kivett, Kivett & Company Communications
tkivett@kivettandco.com
212.727.2935

Heather Varela, Symphony Health Solutions
heather.varela@symphonyhealth.com
602.463.7838

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

Symphony Health Solutions Adds Three Senior Executives and New Board Member

John Milana named CFO; Jon Rosan joins as General Counsel; Nigel Pratt becomes CTO; and Dr. Hari Mahadevan appointed as Board member

Horsham, PA, August 29, 2012

Symphony Health Solutions, owned by Palo AltoA based strategic equity firm Symphony Technology Group, today announced the hires of three new senior executives and a new member of its Board of Directors. John Milana joins the company as Chief Financial Officer, Jon Rosan has been named General Counsel, and Nigel Pratt has accepted an appointment as CTO. Milana and Rosan are based in the firm’s Horsham, Pa., office; Pratt is based in Phoenix. In addition, Dr. Hari Mahadevan has been appointed to the company’s Board in an active advisory role.

As Symphony Health Solution’s CFO, John Milana brings a successful track record of financial and operational leadership for technology and information services businesses. For the past five years, he served as the CFO for SunGuard Higher Education, a software and services business focused on the higher education market. He previously held financial leadership positions at SAP America, Sony Electronics, and IMS Health, where he was Chief Financial Officer for the Americas. Milana is a CPA and holds a B.S. from Rider University.

As Symphony Health Solution’s General Counsel, Jonathan Rosan brings nearly 20 years’ experience in intellectual property licensing, corporate governance and commercial transactions. Most recently, he was General Counsel for Rosetta, an interactive marketing agency with a heavy focus on the health and pharmaceutical industries. Previous roles included General Counsel and Secretary for And 1, a privatelyAheld footwear and apparel company and General Counsel for the International Fight League, a publiclyAtraded entertainment company, as well as Senior Counsel for Moody’s
Analytics, an affiliate of Moody’s Investor Services. Rosan received undergraduate and law degrees from the University of Pennsylvania. He began his legal career as an associate with Drinker Biddle & Reath, a large corporate law firm.

As Chief Technology Officer (CTO), Nigel Pratt brings Symphony Health Solutions more than 27 years’ software engineering experience and deep knowledge of optimizing large
multiAterabyte databases and analytics. He has held posts here in the U.S. and in the U.K. including SVP of Software Development for market research firm Symphony IRI, VP of Engineering at Symphony RPM, VP of Software Development at i2 Technologies, and VP of Software Development at Aspect Development, Inc. Pratt holds a B.S. from Southampton Solent University in the U.K.

Dr. Hari Mahadevan joins the Symphony Health Solutions Board with a wealth of diverse experience as a corporate leader and business consultant to the Healthcare sector. Most recently, he held the post of Executive Officer with Rosetta where he developed and led both its largest vertical – Healthcare – and its Consulting Practice and helped grow the company from $4M of revenue in 2002 to over $200M at its point of sale to Publicis in 2011. Mahadevan also is on the faculty of the Wharton School of Business where he designed and teaches an MBA course on Healthcare Marketing. Previously, he was a management consultant at McKinsey & Company for five years focusing on the pharmaceutical and biotech industry. He has also held senior technical positions in both
Merck and Celgene and worked as a Research Scientist at NASA. He holds a Ph.D. from North Carolina State University and an M.B.A from University of Pennsylvania’s Wharton School.

“Our mission at Symphony Health Solutions is to be a strategic partner to our clients in the transformation of the health information and analytics industry. The addition of John, Nigel, Jon and Hari helps us take a strong step forward to improve the operational and customer centricity of our key finance, legal, technology and Board leaders, and adds strong talent for our investment in innovation,” said Romesh Wadhwani, CEO, Symphony Technology Group. “They are all strong team players with a great record of success in previous roles, and they will help us drive our strategy of growth through
innovation, and will help the organization to deliver on its promise. We feel very positive about the future of our business, and are thrilled to have this caliber of talent share our vision for success.”

About AlphaDetail
AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.alphadetail.com.

About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry.  Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace.  Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions.  The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients.  These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning.  ImpactRx is a Symphony Health Solutions company (www.symphonyhs.com) and AlphaDetail (www.alphadetail.com) is ImpactRx’s global custom market research unit.  For more information, visit: www.impactrx.com.

About Symphony Health Solutions
Symphony Health Solutions provides comprehensive and multi-dimensional understanding of relevant information necessary to measure performance and inform strategies for optimal business decision-making. Focused on conveying value through information to the life sciences and healthcare industries, each of its units brings deep sector expertise and innovation in the delivery of insight to our client partners.

Comprised of AlphaDetail, ImpactRx, Source Healthcare Analytics and TargetRx, the company connects a broad set of research, analytics and health information products that together form a leading performance measurement group. On this strong collaborative platform, Symphony Health Solutions builds innovative solutions to unite information with insight, and deliver high-value knowledge products that enable clients to operate within an evolving healthcare ecosystem.   For more information, visit: www.symphonyhs.com.

For media information, please contact:

For ImpactRx:
Patrick Angelastro, ImpactRx.
pangelastro@impactrx.com
215.444.8988

For AlphaDetail
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

For Symphony Health Solutions
Heather Varela
heather.varela@symphonyhealth.com
(602) 463-7838

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Healthcare Market Research Leader, Once Again Named to the Honomichl Top 50

- only healthcare-focused custom researcher to be included for a second year -

San Mateo, California, July 2, 2012

AlphaDetail Inc., a Symphony Health Solutions company and leader in global healthcare primary market research and influence network mapping, has once again been named as one of the Honomichl Top 50 market research firms in the United States.  The 2012 Honomichl Report, which ranks the 50 largest market research firms based on their US revenue achievement, was published in the June issue of the American Marketing Association’s Marketing News.

“We’re honored to be included in the Honomichl 50 list for the second year in a row”, said Rishi Varma, AlphaDetail’s CEO.  “Since the company’s inception almost twelve years ago, we have focused on building our business through an unparalleled commitment to our clients and to execution excellence”, he continued.  “Honomichl’s recognition of our achievement is a reflection of our relentless customer focus and of the world-class talent, technology and teamwork at AlphaDetail”, Varma concluded.

The company’s 2011 performance, which is the basis for the Honomichl ranking, was fueled by continued growth in global studies, early stage forecasting and market modeling projects, ATU/Tracking solutions, and integrated KOL mapping studies.

“We saw in AlphaDetail an exceptional global custom research firm with analytical expertise that, when combined with ImpactRx’s unique data assets and skill set would enable us to greatly expand the value we provide our biopharmaceutical clients”, said Gregory Ellis, ImpactRx’s President and CEO. “AlphaDetail’s continued inclusion in the Honomichl Top 50 Report is a testament to their value in this market space”, continued Ellis.  “Now, with AlphaDetail, ImpactRx and Source Healthcare Analytics united under the newly-formed Symphony Health Solutions, we have even greater foundational breadth to deliver breakthrough solutions to clients , and we look forward to occupying a higher position as a fully integrated entity on next year’s Honomichl list”, concluded Ellis.

About AlphaDetail
AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.alphadetail.com.

About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry.  Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace.  Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions.  The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients.  These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning.  ImpactRx is a Symphony Health Solutions company (www.symphonyhs.com) and AlphaDetail (www.alphadetail.com) is ImpactRx’s global custom market research unit.  For more information, visit: www.impactrx.com.

About Symphony Health Solutions
Symphony Health Solutions provides comprehensive and multi-dimensional understanding of relevant information necessary to measure performance and inform strategies for optimal business decision-making. Focused on conveying value through information to the life sciences and healthcare industries, each of its units brings deep sector expertise and innovation in the delivery of insight to our client partners.

Comprised of AlphaDetail, ImpactRx, Source Healthcare Analytics and TargetRx, the company connects a broad set of research, analytics and health information products that together form a leading performance measurement group. On this strong collaborative platform, Symphony Health Solutions builds innovative solutions to unite information with insight, and deliver high-value knowledge products that enable clients to operate within an evolving healthcare ecosystem.   For more information, visit: www.symphonyhs.com.

For media information, please contact:

For ImpactRx:
Patrick Angelastro, ImpactRx.
pangelastro@impactrx.com
215.444.8988

For AlphaDetail
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

Symphony Technology Group Acquires Source Healthcare Analytics from Wolters Kluwer; will Combine with Impactrx, TargetRx and Alphadetail to Create Symphony Health Solutions

New Company to Drive Innovation in Information and Analytics across Healthcare

Palo Alto, CA. – May 15, 2012

Symphony Technology Group (STG), a strategic private equity firm with the mission of investing in and building software, data and technology-enabled services companies, today announced that it has acquired Source Healthcare Analytics, LLC from Wolters Kluwer. Terms of the deal were not disclosed.  STG will combine Source Healthcare Analytics with existing portfolio company, ImpactRx, which acquired AlphaDetail and TargetRx during the last year, to form Symphony Health Solutions, which will be focused on delivering high-value data, analytics, and technology based solutions for clients across life science manufacturers, payers, and providers.  

“The healthcare ecosystem is undergoing dramatic change,” said Dr. Romesh Wadhwani, Chairman and CEO of STG. “We believe it is critical for major participants in the industry to transform their commercial approaches informed by analysis and insight, and they need innovation from their service providers to drive change. With Symphony Health Solutions, we will create a high-value, high-impact organization focused on the healthcare industry that will help customers dramatically improve their performance, productivity and profitability.”

Source Healthcare Analytics (SHA) pioneered the physician-level targeting environment that pharmaceutical companies use today, providing strategic market data that analyzes the industry from the perspectives of providers, payers and patients to a variety of private and public organizations. ImpactRx, an STG portfolio company since April 2011, provides the biopharmaceuticals industry with insights into the impact of promotion on physicians’ attitudes and prescribing behavior. During the last year, ImpactRx expanded its breadth of solutions with the acquisitions of TargetRx and AlphaDetail, to become the leading provider of promotional effectiveness solutions to the industry.   

These four businesses will come together under Symphony Health Solutions. The businesses will be integrated over time, beginning with offering strong joint value propositions for clients. The current leaders of the businesses, Greg Ellis, President and CEO, ImpactRx; Bob Jansen, President Source Commercial & GM and Michelle Woker, President Source Operations, will continue in their respective roles.
   
“Our strategic intent when we acquired ImpactRx a year ago was to build a differentiated solutions company in life sciences capable of delivering compelling value through insights informed by data,” said J.T. Treadwell, Managing Director with STG. “By taking this step, and building upon our earlier acquisitions of TargetRx and AlphaDetail, we have greatly accelerated our ability to deliver comprehensive value across a range of commercial decisions, and deliver patient centric insights at a unique scale. We are very enthusiastic for the next phase.” 
 
“Biopharmaceutical companies are facing increasingly complex challenges regarding how to most effectively allocate resources across all stages of the life cycle, and commercial models that worked a decade ago are increasingly less useful,” said Gregory Ellis, President and CEO of ImpactRx. “Our vision is simple: to transform biopharmaceutical marketing through delivery of enhanced information, analytics and solutions that integrate across patients, prescribers and payers, as well as promotional activity.”

“We are thrilled to be a part of the larger Symphony Health Solutions vision,” said Bob Jansen. “STG is a strong technology and innovation-driven investor, and they are a uniquely-suited partner for us to continually grow our value proposition.” Michelle Woker noted, “Bringing together SHA’s world-class secondary data assets with ImpactRx’s proprietary syndicated data set and analytical and therapeutic expertise will enable our combined new company to deliver the comprehensive, multi-channel solutions our clients need.”

About Source Healthcare Analytics
Source Healthcare Analytics (Phoenix, AZ) is a leading provider of information and analytics to the pharmaceutical, biotech and financial industries. The company’s brands include Source®, ProMetis™ and inThought™. A longstanding provider of market data and healthcare analytics, Source offers a unique set of comprehensive patient and physician-level prescribing and usage data. ProMetis provides a three-dimensional market view of prescriber, patient and payer activity in a breakthrough, integrated platform. Led by a team of industry veterans with extensive sell-side research experience, inThought delivers actionable market research reports read by pharmaceutical and healthcare professionals worldwide.

About ImpactRx and AlphaDetail
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry.  Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace.  Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions.  The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients.  These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning. AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.impactrx.com and  www.alphadetail.com.

About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and being a partner in building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver more value to clients to retain and attract the best talent, and to achieve best-in-class business performance. All STG portfolio companies are expected to grow through innovation. STG’s current portfolio consists of 15 global companies with combined revenue of $2.5 Billion, and 15,000 employees spread evenly across North America, Europe and Asia. For more information, visit: www.symphonytg.com

For media information, please contact:

For STG:
Carol Sacks, TENOR Communications
carol@tenorcom.com
650.520.8261

For Source Healthcare Analytics:
Heather Varela, Source Healthcare Analytics
Heather.varela@source.wolterskluwer.com
602.463.7838

For ImpactRx:
Patrick Angelastro, ImpactRx.
pangelastro@impactrx.com
215.444.8988

For AlphaDetail
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

IMPACTRX ACQUIRES ALPHADETAIL - addition of AlphaDetail’s global custom market research expertise enhances and expands company’s solutions offerings

Horsham, PA – March 23, 2012

ImpactRx, a Symphony Technology Group (STG) company, and the pioneer in measuring the impact of promotion on physicians’ attitudes and prescribing behavior, announced today that it has acquired AlphaDetail, Inc., a leader in global healthcare primary market research and influence network mapping. AlphaDetail was recently named one of the top fifty US market research firms in the annual Honomichl survey. Financial terms of the transaction were not disclosed.

AlphaDetail will be closely integrated across ImpactRx’s operations, but will maintain its name and branding and will operate as the custom market research unit of the company.  AlphaDetail’s existing management team will continue to lead the unit and Rishi Varma, AlphaDetail’s current CEO, will also become Executive Vice President, Custom Market Research, ImpactRx and will report to ImpactRx President and CEO, Gregory Ellis. 

“We are very excited to add AlphaDetail’s custom research expertise and consultative approach to ImpactRx’s broad portfolio of promotional effectiveness and consulting analytics solutions,” declared Ellis.  “AlphaDetail’s deep understanding of client needs and exceptional analytical talent will enable ImpactRx to provide incremental value to our clients,” Ellis stated.  “For example, clients’ product forecasting needs will be better served by integrating AlphaDetail’s trusted ability to develop and conduct actionable research with ImpactRx’s data assets and capabilities,” concluded Ellis. 

“We are thrilled to join ImpactRx at this stage in the company’s development,” said Rishi Varma, AlphaDetail’s CEO.  “Since AlphaDetail’s inception eleven years ago, we have focused on building our business through an unparalleled commitment to our clients and to execution excellence,” Varma continued.  “We’re eager to begin integrating this focus and our skill set with ImpactRx’s unique research model and world-class data and analytical assets to deliver even more value to our combined customer base,” concluded Varma.

“Our strategic intent when we acquired ImpactRx almost one year ago was to build a differentiated solutions company in life sciences capable of delivering compelling value through insights informed by data,” said J.T. Treadwell, Managing Director with STG.  “AlphaDetail is a great organization with a reputation for quality work and highly satisfied customers, as is ImpactRx.  The addition of AlphaDetail’s strong global custom research expertise, analytical skill and therapeutic knowledge to ImpactRx’s innovative and extensive promotional effectiveness capabilities will enable us to significantly broaden our footprint as a best-in-class solutions provider,” Treadwell stated. 

About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry.  Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace.  Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions.  The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients.  These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning.  ImpactRx is a Symphony Technology Group company (www.symphonytg.com) and AlphaDetail (www.alphadetail.com) is ImpactRx’s global custom market research unit.  For more information, visit: www.impactrx.com.

 About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver maximum value to clients, to retain and attract the best talent, to drive growth through innovation, and to achieve best-in-class business performance.  STG's current portfolio consists of fourteen global companies with combined revenue of $2.5 billion and 15,000 employees spread across North America, Europe and Asia.  For more information, visit: www.symphonytg.com.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Inc. Names Anthony Quagliata to Position of Director, Sales & Marketing

San Mateo, California – October 13, 2011

AlphaDetail Inc., a leader in global healthcare market research and influence network mapping, has named Anthony Quagliata to the role of Director, Sales and Marketing.

Mr. Quagliata, who previously held the position of Vice President, Client Development at Harris Interactive, will be responsible for organization-wide sales and marketing efforts as well as supporting new product development at AlphaDetail. "I am truly excited to join AlphaDetail, a company with one of the strongest reputations in healthcare market research, a large and active panel of healthcare professionals, and cutting-edge technology solutions”, said Mr. Quagliata.

In his new role, Mr. Quagliata brings over 11 years of healthcare industry experience from various sales, consulting, and market research roles.

Rishi Varma, AlphaDetail’s CEO, said, “We are excited that Anthony has joined our team to bolster AlphaDetail’s exceptional growth in the US and global market research industry.  We look forward to working with Anthony to continue to deliver the highest quality research for our clients”.

Mr. Quagliata holds an MBA from New York University's Stern School of Business, and a BA in Molecular Biology and Philosophy & Religion from Colgate University.

About AlphaDetail, Inc.:

AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. Client satisfaction and execution excellence are core to AlphaDetail’s mission, demonstrated by client satisfaction scores that are among the highest in the industry.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Healthcare Market Research Specialist, Named to the Honomichl Top 50

San Mateo, California – June 20, 2011

AlphaDetail Inc., a leader in global healthcare primary market research and influence network mapping, has been named as one of the top 50 market research firms in the United States.

Rishi Varma, AlphaDetail’s CEO, said “it is a great honor to be part of the Honomichl 50, and a testament to our company’s unique blend of high-touch client service, in-house panel of physicians and allied health professionals, and innovative technology.  Our performance makes us one of the fastest growing companies on the Honomichl 50 and the only company on the list focused solely on custom primary research for the pharmaceutical, biotech, and medical device industries”.

The company’s record performance included major advances across a broad array of clients and product lines.  Major contributors to revenue growth include:

  • Global studies increased 120% with strong growth from Emerging Markets
  • Early stage product profile testing and market modeling increased 114% supported by advances in discrete choice techniques

  • ATU / Tracking solutions increased 44% bolstered by portfolio-wide solutions supported by the AlphaMonitorTM web-based portal

  • KOL mapping increased 17% fueled by key new product enhancements that more closely integrate multiple sources of information into a holistic understanding of influence

  • Revenues from the 5 largest clients grew 48% while the company simultaneously broadened its overall client base

Rishi Varma continued, “We celebrate this achievement with client satisfaction scores among the highest in the industry, continued strong growth, an expanding portfolio of offerings, and a world-class team.  We welcome pharmaceutical and biotech clients who have not experienced AlphaDetail to reach out to us to learn more”.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail AlphaPulseTM: Anticipated Impact of CATT Trial in Wet AMD Treatment

San Mateo, California – May 16, 2011

On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing “Comparisons of Age-Related Macular Degeneration Treatments Trials” (CATT).

AlphaDetail Inc., a leader in global ophthalmology primary market research and influence network mapping, has its latest AlphaPulseTM survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.

Amy Tsang, a Director at AlphaDetail, explained “the use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue”.

While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.

  • 68% of surveyed Ophthalmologists are currently aware of the CATT trial results.
  • Perceived Benefits of Avastin
    • Over three-quarters of Ophthalmologists agree that the results from the CATT trial provide evidence that Avastin’s cost savings outweigh its potential risks in Wet AMD.  

    • Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue among newly diagnosed patients in the future.

    • Based on the CATT trial results, Ophthalmologists intend to switch 10-15% of their Wet AMD patients currently on Lucentis to Avastin over the next 6 months.
  • Perceived Benefits of Lucentis

    • Two-thirds of Ophthalmologists agree that Lucentis’ superiority over Avastin in other efficacy-related attributes, such as lowering retinal thickness and decreasing retinal fluid, are important considerations when selecting the appropriate therapy for their patients.
    • Similarly, two-thirds of Ophthalmologists agree that data supporting equivalent long term efficacy between Lucentis and Avastin is still needed.
    • Finally, Ophthalmologists are divided on their level of concern about mortality rates and risk of hemorrhagic stroke with Avastin compared to Lucentis as shown in an analysis of 77,886 Wet AMD patients on Medicare.

 

To learn more about this study and to receive full results, please contact Amy Tsang at Amy.Tsang@alphadetail.com or (650) 581-3127.

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering

San Mateo, California – March 28, 2011

AlphaDetail, a leader in global primary market research for the pharmaceutical and biotech industries, just completed a year of record revenue and profitability, making it one of the fastest growing market research companies in the United States.
 
“On March 21, 2011 – the first day of spring – AlphaDetail celebrated its 10 year anniversary”, announced Rishi Varma, President & CEO.

The company has a long history of philanthropy, supporting a wide range of causes over the years.  These include helping victims of devastating natural disasters far from home (e.g. Southeast Asia Tsunami, Hurricane Katrina, Haiti Earthquake, Japan Earthquake and Tsunami) as well as supporting and helping the company’s local communities (e.g. SF AIDS Walk, Habitat for Humanity, Save the Bay).

AlphaDetail employees volunteered at three organizations on March 21: two in the San Francisco Bay Area, and one in the Horsham, PA area.

  • MedShare in San Leandro, CA is an organization that distributes medical supplies to communities in need around the world.  Their shipments of medical supplies and equipment have brought healing and the promise of better lives to 85 countries and countless patients.
  • Manna on Main Street in Landsale, PA was founded in 1981 and has grown to be a place where those seeking help and those willing to help have gathered to work together. Manna provides a soup kitchen and food cupboard, and a variety of other programs to help individuals in need. The vision of Manna on Main Street is "that everyone might be fed."
  • The SF Food Bank, in San Francisco, CA collects millions of pounds of food from growers, packers, processors, manufacturers, the USDA and grocery stores.  Volunteers sort, repack and shelve over 350 tons of food at our warehouse every week.  In all, the SF Food Bank serves over 147,000 people each year.

 

Rishi Varma explained, “I personally can’t think of a more appropriate way to commemorate our 10-year anniversary than by helping those who are less fortunate than us”.
 

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Revenue Soars 30% in 2010

San Mateo, California - February 10, 2011 / PRNewswire

AlphaDetail, a leader in global primary market research for the pharmaceutical and biotech industries, reported a 30% increase in revenue in 2010, exceeding $18.5M in annual revenue for the first time in the company’s history.

“Our clients have delivered a loud and clear message that AlphaDetail provides the marketing research solutions that get at the heart of their strategic information needs” says Rishi Varma, CEO and President of AlphaDetail. “Our performance in 2010 makes us one of the fastest growing market research companies in the United States”.

The company’s record performance included major advances across a broad array of clients and product lines.  Major contributors to revenue growth include:

  • Global studies increased 120% with strong growth from Emerging Markets
  • Early stage product profile testing and market modeling increased 114% supported by advances in discrete choice techniques
  • ATU / Tracking solutions increased 44% bolstered by portfolio-wide solutions supported by the AlphaMonitorTM web-based portal
  • KOL mapping increased 17% fueled by key new product enhancements that more closely integrate multiple sources of information into a holistic understanding of influence
  • Revenues from the 5 largest clients grew 48% while the company simultaneously broadened its overall client base.

Rishi Varma continued, “We approach AlphaDetail’s 10 year anniversary with strong growth, an expanding portfolio of offerings, a world-class team, and the highest client satisfaction scores in the industry”.
 

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

FOR IMMEDIATE RELEASE

Turning the Tables on Measuring Client Satisfaction

San Mateo, California - April 7, 2010 / PRNewswire

With nearly a decade’s experience assisting our clients effectively launch and commercialize new prescription therapies, vaccines and medical devices, AlphaDetail, a global leader in primary marketing research, decided to turn the tables and do a quantitative analysis of something new: its own customer satisfaction.

“We work closely with our clients to design studies that provide insights to help our clients optimize their brand performance” says Rishi Varma, CEO and President of AlphaDetail. “Starting in 2009, we decided to put our money where our mouth is by measuring the success of our own performance”.

The cumulative % Top 2 Box results as of the end of June, 2010 are provided below.

Overall satisfaction with AlphaDetail – 98%
Likelihood to recommend AlphaDetail – 98%
Study design / methodology recommendations – 98%
Questionnaire / discussion guide design – 93%
Respondent recruiting – 94%
Timeliness of deliverables – 98%
Client service – 98%
Insightfulness of final presentation – 92%
Therapeutic area knowledge – 94%

View the survey results and client quotes

Rishi Varma went on to say “From the day we opened our doors for business in 2001, we have been driven by an unbending commitment to excellence.  The entire AlphaDetail team is delighted by our client satisfaction survey results and the validation that we are indeed achieving our vision”.
 

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Launches RapidRecruit: A New Healthcare Market Research Field and Tab Service

San Mateo, California - July 22, 2010 / PRNewswire

AlphaDetail, an innovator in pharmaceutical marketing research, is proud to launch RapidRecruit, an expansion of its healthcare field and tab services for market research organizations, ad agencies, and consulting firms that need a fieldwork partner.

AlphaDetail has built and maintains a large US network of physicians and healthcare providers.  This network of active participants allows AlphaDetail and our customers to field large studies quickly and cost effectively. 

AlphaDetail’s in-house programming and quality assurance staff has extensive experience developing complex surveys for the healthcare market utilizing the Confirmit software platform and the latest in conjoint survey design using Sawtooth Software.  Clients also have access real-time data reporting through the AlphaMonitor™ reporting portal.

Roger Jensen, Vice President of Operations at AlphaDetail, said that “AlphaDetail RapidRecruit is an exciting opportunity for us to offer the broad coverage of our active network, programming, and fielding expertise to customers who need rapid, cost-effective fielding of market research studies”. 

To learn more about AlphaDetail RapidRecruit, please contact Roger Jensen, Vice President of Operations at Roger.Jensen@rapidrecuit.com or (650) 581-3146 or visit us at http://www.rapidrecruit.com.
 

About AlphaDetail RapidRecruit:

AlphaDetail RapidRecruit is an independent fielding organization within AlphaDetail, Inc.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as market research, advertising, and consulting organizations.

Contact Information:

Roger Jensen, Vice President of Operations
(650) 581-3146
Roger.Jensen@rapidrecuit.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Names Rishi Varma to Serve as President and CEO

San Mateo, California - January 18, 2010 / PRNewswire

AlphaDetail, an innovator in pharmaceutical marketing research, is pleased to announce that Rishi Varma has been appointed President and CEO by the Board of Directors, effective January 1, 2010.

Mr. Varma co-founded AlphaDetail almost nine years ago and has held senior level positions at AlphaDetail, overseeing each major functional area of the business.  In addition, he has worked closely with pharmaceutical and biotech clients on designing and implementing hundreds of marketing research studies.  This experience, combined with his 14+ years working in the pharmaceutical and biotech industries, serves Mr. Varma well as he assumes the duties of the CEO.

Carl Spetzler, an AlphaDetail board member, said "Rishi was the natural choice for President & CEO given his history with the company and deep understanding of our core business. We are impressed by Rishi’s emphasis on hiring and developing the highest quality market research professionals, his insight into the forces that will shape our industry in the future and the level of mutual respect he shares with his clients, employees, and partners."

Mr. Varma said, “I am excited to take on this expanded role at AlphaDetail.  We have just completed our most successful year in the company’s history, and I look forward to building on our successes by continuing to focus on high research quality, an unparalleled commitment to client service, a strong and growing panel of respondents, and cutting-edge technology.”

Prior to AlphaDetail, as a senior engagement manager for Strategic Decisions Group (SDG), Rishi helped top tier pharmaceutical companies in strategic development and process design throughout the R&D and marketing value chain.  He also led the development of the SDG biotech practice.

Rishi holds a B.S. in industrial engineering and a M.S. in decision analysis from Stanford University.

To learn more about AlphaDetail, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116. , or visit us at http://www.alphadetail.com/corp/Home.do

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

Tracking Studies: The Advantage of Integration and Speed

San Mateo, California - October 20, 2009

AlphaDetail, an innovator in pharmaceutical marketing research, is pleased to introduce two new features to its suite of tracking services: AlphaLink and AlphaMonitor.

AlphaLink helps clients better understand their competitive landscape by integrating secondary research with tracking study results. “One of the biggest issues facing clients today is managing through vast amounts of data, gathered from a number of different sources,” says Rishi Varma, co-founder of AlphaDetail. “AlphaLink provides an integrated view of a market, enabling a more focused, holistic market understanding.”

AlphaMonitor provides real-time online access with up-to-the-minute results for any of the company’s tracking services – from continuous tracking to monitoring key variables in periodic tracking studies. “Pharmaceutical and biotech marketers are frequently looking for fast insights to react to market changes” reports Dave Johnson, Vice President of AlphaDetail’s Professional Services team. “AlphaMonitor offers instant views and dynamic access to study results that enable marketers to quickly understand and react to feedback from the market.” 

To learn more about AlphaDetail’s Tracking services, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116. , or visit us at http://www.alphadetail.com/corp/Home.do

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

Physicians Anticipate Higher Prescribing Based on JUPITER Study

San Mateo, California - November 21, 2008

Just three days after the JUPITER trial results were presented at the American Heart Association meeting and simultaneously published online by the New England Journal of Medicine, an AlphaDetail survey of more than 100 primary care physicians shows that physicians anticipate a 14% increase in the use of drug therapy among their hypercholesterolemia patients, particularly for low to moderate risk patients.

The JUPITER study showed that CRESTOR (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events by 44% compared with placebo among men and women with elevated high-sensitivity C-reactive protein (hs-CRP) but low to normal low density lipoprotein cholesterol (LDL-C).

News about JUPITER spread quickly: Two-thirds of the physicians surveyed were already aware of the study results within days of its release. Nearly 90% of the physicians surveyed report that they found the study results to be positive, emphasizing how compelling they found the findings. However, some physicians feel more data is needed and question if this benefit applies to all statins or is specific to CRESTOR.

Physicians report that they recognize the value of C-reactive protein. Two-fifths of physicians indicate that they strongly or very strongly agree that hs-CRP plays an important role in cardiovascular disease. The most intriguing part of the 2008 study lies in physicians future expectations. Following the JUPITER study results, physicians report that they anticipate more than doubling the percent of patients for whom they test hs-CRP. The increased testing is likely to drive future prescribing behavior, particularly for patients with low to moderate risk factors.

Please contact Rishi Varma at AlphaDetail for more information on the AlphaPulse study results or for additional insight regarding the market impact of the JUPITER study.

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Continues Bi-coastal Expansion

San Mateo, California - November 4, 2008

AlphaDetail Inc. is growing.  As a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, the company is pleased to announce the addition of 3 new senior staff members to its Professional Services Group.   

Gloria Lee is a Director of Professional Services, based in Alphadetail’s San Mateo, California headquarters office.  Gloria comes to AlphaDetail from Yahoo where she had been the Director of Monetization.  Prior to Yahoo , Gloria spent seven years and Duff & Phelps, most recently as Director of Market & Financial Analytics Healthcare Practice.  Gloria has also held positions as a Consultant at ZS Associates and as a Senior Manager of Strategic Planning and Development at Pfizer.  She holds an S.M. in Operations Research from M.I.T., as well as an M.A. and B.A. in Mathematics from the University of Cambridge.

Jim Daly is a Senior Director of Business Development, based in AlphaDetail’s Horsham, Pennsylvania office.  Jim has more than 18 years of pharmaceutical consulting and business experience.  Prior to joining AlphaDetail, Jim worked at Innovex where he supported clients with Contract Sales Force Deployment services, including Physician Targeting & Alignment solutions.  Jim also held senior positions at IMS Health and Health Products Research, where he developed business solutions in the areas of Portfolio Optimization & Resource Allocation, Strategic Product Planning, Marketing Research & Quantitative Analysis.  Jim earned his BS degree in Business Management from Montclair State University.

John Unipan is a Director of Professional Services, also based in the Horsham, Pennsylvania office.  John has over 15 years of healthcare and pharmaceutical experience.  John has supervised and led hundreds of market research studies for leading pharmaceutical, biotech and medical device manufacturers.  Previously John worked for Psyma Incorporated, TagetRx and GfK.  John is an expert in designing and conducting quantitative analysis, and has also personally conducted hundreds of interviews and focus groups with physicians, patients and other healthcare professionals.  John received his Bachelor of Arts degree from Bowdoin College and studied Applied Social Psychology at the graduate level at the Claremont Graduate University.

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail AlphaPulseTM: Most Practicing Physicians React Positively to FDA Panel’s Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

San Mateo, California - July 7, 2008

After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk.  85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.

On July 3rd AlphaDetail launched its latest AlphaPulseTM survey to measure immediate physician awareness and reactions to the panel recommendation.  In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:

  • Unaided, about 40% of physicians mentioned CV risk associated with diabetes medications as the most important development in diabetes treatment from the past month.
  • When prompted, half of physicians indicated they had heard about the FDA panel recommendation to require cardiovascular safety trials for new diabetes medications - only a day after the news was announced.
  • Although most physicians from both specialties support the recommendation, twice as many cardiologists (33%) vs. endocrinologists (16%) agree strongly with it.
    • However, 22% of endocrinologists disagree with the recommendation primarily because they believe it would stifle innovation and delay the availability of important new therapies.
  • Physicians disagree on the most appropriate implementation of the FDA panel recommendation - two CV safety trials vs. only one trial.
    • However, more physicians believe that the two trial implementation is the most appropriate.
  • Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious but has CV risk to patients that have no CV risk factors other than diabetes.
    • Physicians have to make a trade-off between controlling diabetes and preventing other diabetes complications vs. preventing CV risk.

 

To learn more about this study, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

ASCO Results: Oncologists Rank Genentech Number One

San Mateo, California - June 9, 2008

When asked which company stood out at last week’s ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.

In a brief on-line survey of 103 oncologists conducted soon after the close of the conference, AlphaDetail was able to gather some interesting feedback about oncologist perceptions of the meeting.  The ASCO Annual Meeting attracts more than 30,000 attendees and is considered the premier educational and scientific event in the oncology community.

  • 60% of US oncologists attended the ASCO Annual Meeting.
  • Oncologists rate Genentech #1 on overall image in oncology and cite it as the top company that stood out above the others at ASCO.
  • Oncologists cite the following as the three most important pieces of data presented at ASCO:
    • KRAS status predicts response to first-line cetuximab for metastatic colorectal cancer.
    • Erbitux (cetuximab) + platinum-based chemotherapy extends overall survival in NSCLC vs. chemotherapy alone.
    • Zometa (zoledronic acid) increases survival for premenopausal patients who received adjuvant endocrine therapy for early breast cancer.

To learn more about this study, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Announces Launch of New Web-Based KOL Online Reporter (KOLORTM)

San Mateo, California - April 18, 2008

Key Opinion Leader reporting never looked easier. AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the global Life Sciences industry, is proud to announce KOLORTM, a web-based Key Opinion Leader report system that dramatically enhances product deliverables.

KOLORTM brings a variety of benefits to AlphaDetail’s KOL identification process including:

  • Faster results
  • Customizable data presentation configurations
  • Advanced and user friendly search filters.

KOLORTM supports AlphaDetail’s unique KOL identification process, including the integration of primary and secondary research, as well as in-depth KOL profiles. Users are able to configure virtually every aspect of data presentation instantly – column display names, order, and format to name a few.  Clients benefit from secure, 24-hour access and multiple users are able to generate, share, and export custom reports simultaneously.

Additionally, the new web-based tool paves the way for future advances, including the ability to plot nominated and surveyed physicians on Google Maps and an integrated social-network mapping tool to generate network charts. AlphaDetail is pleased to introduce KOLORTM, a unique and powerful KOL reporting tool, as an excellent compliment to the company’s  rigorous and comprehensive KOL product offerings.

To learn more about AlphaDetail’s KOL mapping solution please visit http://www.alphadetail.com/KOL

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Expands Management Team

San Mateo, California - February, 28

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, is proud to announce the addition of Dave Johnson to its management team. Dave joined AlphaDetail in January and serves as the Vice President of Professional Services in the company's Horsham, PA office.

Dave brings AlphaDetail a wide variety of industry-pertinent analytical skills and management experience that will impact the company immediately. During his 15 years of experience in the pharmaceutical industry, he spent the last nine years working for Verispan, most recently as Vice President of the company's 100-person Client Solutions team. In this role, Dave was responsible for managing the company's consulting and marketing research services, supporting virtually all of the industry's leading pharmaceutical and biotech organizations. Prior to Verispan, Dave worked on the marketing research team at Warner-Lambert, supporting the cardiovascular and women's health teams. Dave's other variegated marketing and marketing research experience includes roles at Scott-Levin, Arbitron ratings, IMS Health (London office) and Life Fitness (Munich office).

AlphaDetail CEO Roger Jensen explains, "Dave's background and depth of experience will bring immediate benefits to AlphaDetail. Dave's demonstrated leadership in pharmaceutical market research makes him the ideal person to help us continue our growth and maintain the commitment to quality that our customers expect from AlphaDetail."

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Expands Qualitative Research Capabilities

San Mateo, California - January, 16

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, continues to affirm its commitment to growth and client service by expanding its Qualitative Research Capabilities.

Beth Thompson joined AlphaDetail in December as Director of the qualitative research department. Beth has over 14 years healthcare marketing research and consulting experience, during her tenure at GfK Strategic Marketing, Britnall & Nicolini and as President of her own qualitative consultancy. She is an expert in the area of qualitative research with extensive experience moderating telephone interviews, in-person interviews, dyads/triads, and focus groups.

Beth's experience ranges from pre-launch to post-launch studies and includes exploratory market assessments, pre-positioning/positioning work, concept testing, message development, stimulus testing (detail aids, journal ads, etc.), and war-gaming. She has also conducted qualitative projects in support of quantitative research, such as attribute testing or segmentation analysis. In addition to domestic US-only work, Beth has quite a bit of experience managing large multinational projects as well.

Beth has worked with many of the leading companies in the pharmaceutical industry including Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Pfizer, Novartis, and others. Her work has spanned a broad spectrum of therapeutic areas such as cardiovascular disease, depression/anxiety, diabetes, dyslipidemia, HIV/AIDs, and oncology, to name a few.

Beth has a Ph. D (ABD) in Political Science from Rutger's University and a B.A. in International Relations from the University of Michigan's Honors College.

AlphaDetail CEO Roger Jensen explains, "The addition of an experienced qualitative research professional like Beth is another example of AlphaDetail's commitment to providing an expanding array of services and methodologies to our customers."

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence

San Mateo, California - October 5, 2007

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, continues to affirm its commitment to growth and client service by expanding to a new office on the east coast. 

AlphaDetail, Inc. will open a full service office in Horsham, Pennsylvania on November 1, 2007.  This will benefit a large number of clients located in the Eastern Time Zone by providing more opportunities for in-person project interactions and more frequent client visits while simultaneously bolstering project production capacity. 

AlphaDetail, Inc. CEO Roger Jensen explains, "We are extremely excited about our new East Coast office.  It is an important part of our strategic plan to establish a presence here to ensure we deliver the best possible service to our many East Coast customers.  A local presence will also allow us to attract the area's best professionals in healthcare market research."

To complement this exciting news three talented Directors have joined AlphaDetail, and will all be based in the new east coast office: 

Eileen Henne has over 25 years of healthcare and pharmaceutical experience at a number of pharmaceutical companies such as DuPont Merck, Wyeth-Ayerst and Bristol-Myers Squibb. She has also held positions of increasing responsibility at IMS Health and Health Products Research. Eileen received her Bachelor of Science Degree from Neumann College. 

Mike Nestler has over 20 years of marketing research and consulting experience.  Before joining AlphaDetail, Mike has done a significant amount of consulting and project work for Novartis, Bayer, GSK, Merck, Johnson & Johnson and many others. Mike has a BA in Experimental Psychology from McMaster University in Hamilton, Ontario and an MBA from York University in Toronto. 

John Freeman has over 10 years of experience in pharmaceutical marketing research and consulting for Datamonitor, Instinet, Gerson Lehrman Group and GfK Market Measures. John has a BA in Biology from the University of Pennsylvania and a Master of Philosophy in Pharmacology from the University of Cambridge, UK.

Eileen, Mike, and John all build a strong foundation for growth in AlphaDetail's east coast operation and will guide a diverse and powerful new team that reflects AlphaDetail's ongoing commitment to excellent services and delivering an outstanding product.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

AlphaDetail is a member and abides by the rules and regulations of the following professional organizations.
  • Sitemap
  • Terms of Service
  • Privacy Policy